STAT1-mediated interferon signatures are associated with preclinical JAK inhibitor sensitivity in T-ALL
Abstract
Abstract We used single-cell genomics to characterize a patient with T-cell acute lymphoblastic leukemia treated in the Children’s Oncology Group AALL0434 trial with poor clinical outcome despite favorable genomic features, identifying a STAT1-mediated interferon-related transcriptional signature and inflammatory microenvironment associated with sensitivity to small-molecule JAK inhibition.
Article Details
Authors (37)
Jason Xu
Jonathan H. Sussman
Austin Yang
7Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, PA
Satoshi Yoshimura
Department of Pharmacy and Pharmaceutical Sciences
Jianzhong Hu
Changya Chen
2Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Tiffaney Vincent
3Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
Shovik Bandyopadhyay
2Medical Scientist Training Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Elizabeth Y. Li
3Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
Tristan Lim
7Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Omar Elghawy
2Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
Adam Barsouk
2Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA
Damjan Karanfilovski
7Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Shira L. Wald
7Department of Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Gregory M. Chen
1Graduate Group in Genomics and Computational Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
David Wu
Haley Newman
1Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, United States
Alexander Li
Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138, United States
Yusha Sun
Chia-Hui Chen
5Children's Hospital of Philadelphia, Center for Childhood Cancer Research, Philadelphia, United States
Kathrin Bernt
1Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Oncology, Philadelphia, United States
Brent L. Wood
Department of Pathology and Laboratory Medicine, Children’s Hospital of Los Angeles, Los Angeles
Stuart S. Winter
11Division of Hematology Oncology, Children's Minnesota, Eagan, MN
Kimberly P. Dunsmore
12Division of Oncology, University of Virginia Health Sciences Center, Charlottesville, VA
Elizabeth Raetz
11NYU Langone Health, New York, United States
Meenakshi Devidas
Department of Global Pediatric Medicine, St. Jude Children’s Research Hospital, Memphis, TN
Stanley Pounds
Mignon Loh
13Ben Towne Center for Childhood Cancer Research and the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA
Stephen P. Hunger
Department of Pediatrics and the Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia
Mark Y. Chiang
16Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI
Caroline Diorio
Danika Di Giacomo
1Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
Petri Pölönen
Charles G. Mullighan
Jun J. Yang
Department of Pharmacy and Pharmaceutical Sciences
Kai Tan
David T. Teachey